Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA), and French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Thursday that patient enrolment in the Phase 2b RELIEVE UCCD trial for anti-TL1A drug duvakitug in moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) has completed early due to a significant acceleration in patient recruitment.

Topline results for both UC and CD are now expected in Q4 2024, with detailed results in 2025.

Teva and Sanofi partnered to co-develop and co-commercialise duvakitug in October 2023. Under the terms of the agreement, Teva received USD500m upfront and may receive up to USD1bn in milestones. The two companies share development costs and net profits in major markets, with royalty arrangements in other markets. Sanofi will lead Phase 3 development.

Teva will lead commercialisation of the product in Europe, Israel and specified other countries, while Sanofi will lead commercialisation in North America, Japan other parts of Asia and the rest of the world.